How Much Does Mounjaro Cost in Oregon in 2026?

Oregon Retail Pricing for Brand-Name Mounjaro

The average cash price for brand-name Mounjaro at Oregon retail pharmacies sits at roughly $1,023 per month in 2026, matching Eli Lilly's national list price. That figure applies to a four-week supply of pre-filled injection pens at any dose tier, from the 2.5 mg starter pen through the 15 mg maintenance dose.

Oregon pharmacy pricing follows a familiar pattern seen across the U.S.: independent pharmacies, chain retailers like Walgreens and Fred Meyer, and mail-order services all fall within a narrow band around the list price for cash-pay customers. Price variation between Portland-metro pharmacies and rural locations like Bend or Medford is minimal for brand injectables because wholesale acquisition costs are set nationally by Eli Lilly 1.

This sticker price lands Mounjaro in the same bracket as other branded GLP-1 receptor agonists. For context, SURPASS-2 (N=1,879) demonstrated that tirzepatide 15 mg reduced HbA1c by 2.58% and body weight by 12.4 kg at 40 weeks versus semaglutide 1 mg, which achieved a 1.86% HbA1c reduction and 6.2 kg weight loss 2. The clinical margin between tirzepatide and semaglutide gives prescribers in Oregon a concrete reason to pursue Mounjaro access even when the price tag requires extra paperwork.

Patients filling prescriptions at Oregon-based mail-order pharmacies may find marginally lower dispensing fees, but the drug acquisition cost remains unchanged.

Compounded Tirzepatide in Oregon: Pricing and Legality

Compounded tirzepatide is available in Oregon through licensed 503A compounding pharmacies at approximately $249 per month. That price point reflects the current market for patient-specific compounded preparations and represents a 76% reduction compared to brand Mounjaro.

Oregon follows federal compounding law under the Drug Quality and Security Act (DQSA). A 503A pharmacy operates under a valid prescription for an individual patient, compounding medications that are not copies of commercially available products or that address a documented shortage. The FDA's drug shortage list has included tirzepatide at various points, and during active shortage periods, 503A pharmacies can legally compound tirzepatide 3.

There are clinical tradeoffs. Compounded preparations do not undergo the same bioequivalence testing as FDA-approved products. Potency, sterility, and stability depend entirely on the compounding pharmacy's quality controls. The Oregon Board of Pharmacy oversees 503A facilities in the state, but inspection frequency and depth vary.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "Patients considering compounded GLP-1 receptor agonists should discuss the risks and benefits with their prescriber, including the lack of FDA approval for the compounded product" 4.

Patients filling compounded tirzepatide in Oregon should verify that their pharmacy holds a current Oregon Board of Pharmacy license and ask for certificates of analysis showing potency testing on their specific batch.

Oregon Medicaid (Oregon Health Plan) Coverage

Oregon Medicaid, administered through the Oregon Health Plan (OHP), covers Mounjaro with prior authorization for type 2 diabetes. Weight management alone, without a concurrent diabetes diagnosis, does not currently qualify for OHP coverage of tirzepatide under the Mounjaro label.

The prior authorization process requires prescribers to document a confirmed type 2 diabetes diagnosis (typically HbA1c ≥ 7.0%), failure or intolerance of at least one first-line agent (usually metformin), and a clinical rationale for choosing tirzepatide over other covered options like semaglutide or dulaglutide. Response time from coordinated care organizations (CCOs) ranges from 24 hours for urgent requests to 14 calendar days for standard requests.

Oregon operates Medicaid through 16 CCOs, each with some latitude in formulary management. Providence Health Plan, CareOregon, PacificSource Community Solutions, and AllCare Health each maintain their own prior authorization criteria, though all must comply with the Oregon Health Authority's Practitioner-Managed Prescription Drug Plan (PMPDP) recommendations 5.

The SURPASS clinical program provides the evidence base that CCOs reference when evaluating tirzepatide requests. In SURPASS-2, 86% of patients on tirzepatide 15 mg reached HbA1c <7.0% at 40 weeks, compared to 79% on semaglutide 1 mg 2. That efficacy gap often satisfies the "clinical advantage" criterion in step therapy appeals.

If a prior authorization is denied, Oregon law requires that CCOs provide a written explanation and instructions for filing an appeal. Patients can also request an administrative hearing through the Oregon Health Authority within 90 days of the denial notice.

Commercial Insurance Coverage in Oregon

Most large commercial insurers in Oregon place Mounjaro on their formulary, though tier placement and cost-sharing differ significantly. Here is what patients can expect from the major plans operating in the state.

Providence Health Plan lists Mounjaro on its specialty tier with prior authorization for type 2 diabetes. Copays for specialty-tier drugs typically range from $75 to $150 per fill depending on the specific plan design. Providence is Oregon's largest commercial insurer by enrollment.

Regence BlueCross BlueShield of Oregon covers tirzepatide with prior authorization and step therapy (documented metformin trial). Specialty copays run $50 to $200 depending on the metallic tier of the plan.

PacificSource Health Plans requires prior authorization and covers Mounjaro for type 2 diabetes on its injectable diabetes specialty tier. Members on high-deductible plans face full cost until the deductible is met.

Kaiser Permanente Northwest operates its own pharmacy benefit. Kaiser covers Mounjaro for type 2 diabetes after documented trial of metformin and at least one other second-line agent. Internal formulary management means Kaiser members rarely pay more than $100 per fill after prior authorization approval.

Moda Health and CIGNA plans sold on the Oregon marketplace also cover Mounjaro with varying prior authorization criteria 6.

One consistent pattern across Oregon commercial plans: coverage for weight management (obesity without type 2 diabetes) remains limited. The FDA approved tirzepatide for chronic weight management under the Zepbound label, not the Mounjaro label. Some Oregon employers have added Zepbound coverage to their pharmacy benefit, but individual and small-group plans sold through the Oregon Health Insurance Marketplace rarely cover anti-obesity medications.

The Eli Lilly Mounjaro Savings Card

Eli Lilly's savings card program offers commercially insured patients the chance to reduce their out-of-pocket cost to as low as $25 per monthly fill. The card applies at the point of sale at any participating Oregon pharmacy.

Eligibility requirements: the patient must have commercial insurance (not Medicare, Medicaid, Tricare, or any other government-funded program), must hold a valid prescription for Mounjaro, and the insurance plan must cover Mounjaro at some level. The maximum annual benefit varies by program cycle, but Lilly has historically capped it at $150 per monthly fill or a total annual benefit of $1,800 1.

Activation happens online or by phone. Oregon patients can present the digital card at any pharmacy with an active BIN/PCN/Group number. Processing runs through the pharmacy's adjudication system as a secondary claim after the primary insurance processes.

There are limitations. If your insurance plan does not cover Mounjaro at all (full denial, not just high copay), the savings card may not apply. Patients with $0 copays from their insurance are generally ineligible for additional savings card benefits. The program terms change periodically, so checking the current offer directly from Lilly before each fill is worth the 60 seconds it takes.

Telehealth Access to Mounjaro in Oregon

Oregon permits telehealth prescribing of Mounjaro. No in-person visit is required for an initial tirzepatide prescription under current Oregon Telehealth Parity Law (ORS 743A.058), which mandates that insurers cover telehealth services at parity with in-person visits 7.

This means Oregon residents in rural areas (Klamath Falls, La Grande, Astoria, Coos Bay) have the same prescriptive access as those in Portland or Eugene. A licensed prescriber in Oregon, or one holding an Oregon medical license through the Interstate Medical Licensure Compact, can evaluate the patient via synchronous video, order labs, and transmit the Mounjaro prescription to any Oregon pharmacy.

Several telehealth platforms operating in Oregon specialize in GLP-1 prescribing. Typical consultation fees range from $99 to $249 for an initial evaluation, with follow-up visits at $49 to $99 per quarter. These fees sit on top of the medication cost. Some platforms bundle compounded tirzepatide with the consultation fee at an all-in price of $299 to $399 per month.

Lab work remains part of the clinical standard. The American Diabetes Association's 2024 Standards of Care recommend baseline HbA1c, fasting glucose, renal function, and lipid panel before initiating any GLP-1 receptor agonist or GIP/GLP-1 dual agonist 4. Oregon telehealth providers typically order these through Quest Diagnostics or Labcorp locations throughout the state.

Cost Reduction Strategies Specific to Oregon

Oregon patients have several routes to lower their tirzepatide costs beyond insurance and the Lilly savings card.

Oregon Prescription Drug Program (OPDP): Oregon's state-run discount program negotiates prices for uninsured and underinsured residents. Enrollment is free and available to any Oregon resident without age or income restrictions. OPDP discounts on brand injectables typically fall in the 5% to 15% range, which brings Mounjaro closer to $870 to $970 per month.

Patient Assistance Programs: Eli Lilly's Lilly Cares Foundation provides free Mounjaro to patients with household income at or below 400% of the Federal Poverty Level who lack prescription drug coverage. For a single-person household in 2026, that threshold is approximately $62,400. Application requires prescriber involvement and proof of income.

340B pharmacies: Oregon has over 150 healthcare entities participating in the federal 340B Drug Pricing Program, including federally qualified health centers (FQHCs) like Virginia Garcia Memorial Health Center, La Clínica, and Mosaic Medical. Patients receiving care at 340B-covered entities may access Mounjaro at substantially reduced cost, though specific pricing varies by entity 5.

Compounded tirzepatide: As discussed above, the $249 per month price point from Oregon 503A pharmacies remains the lowest-cost option for patients unable to secure insurance coverage or savings card eligibility.

Manufacturer coupons and periodic promotions: Lilly periodically offers limited-time offers for new patients. These promotions have historically included one free month or a reduced trial period at $25. Checking Lilly's official Mounjaro website before starting therapy can capture these windows.

Clinical Dosing and What It Means for Total Cost

Mounjaro dosing follows a fixed titration schedule: 2.5 mg weekly for the first four weeks, then 5 mg weekly for at least four weeks, with optional increases in 2.5 mg increments to a maximum of 15 mg weekly. Each dose tier uses its own pre-filled pen. The cost per pen box remains the same regardless of dose strength.

This means the total medication cost stays constant across the titration. A patient on 2.5 mg pays the same $1,023 per month as a patient on 15 mg. That pricing structure differs from some older diabetes medications where higher doses cost proportionally more.

The clinical implication: dose optimization matters for efficacy, not cost. In SURPASS-2, the 15 mg dose produced the greatest HbA1c and weight reductions, but the 5 mg dose still achieved clinically meaningful results (1.87% HbA1c reduction, 7.6 kg weight loss at 40 weeks) 2. Patients and prescribers should titrate based on glycemic response and tolerability, not financial pressure to stay at a lower dose.

According to the American Association of Clinical Endocrinology (AACE) 2023 consensus statement: "Dose titration of incretin-based therapies should be guided by glycemic targets and gastrointestinal tolerability, with the goal of reaching the most effective tolerated dose" 8.

A full year of brand Mounjaro at the retail cash price totals approximately $12,276. With the Lilly savings card reducing copays to $25 monthly, the annual patient cost drops to $300 (assuming the card applies to every fill). Compounded tirzepatide at $249 per month totals $2,988 annually.